Mengen 500mg Namibia - englanti - Namibia Medicines Regulatory Council

mengen 500mg

novagen pharma (pty)ltd - metformin hydrochloride - tablet - each film-coated tablet contains metformin hydrochloride 500 mg

Mengen 850mg Namibia - englanti - Namibia Medicines Regulatory Council

mengen 850mg

novagen pharma (pty)ltd - metformin hydrochloride - tablet - each film-coated tablet contains metformin hydrochloride 850 mg

Mengen 1000mg Namibia - englanti - Namibia Medicines Regulatory Council

mengen 1000mg

novagen pharma (pty)ltd - metformin hydrochloride - tablet - each film-coated tablet contains metformin hydrochloride 1000 mg

Mastergraft Putty - Bone implant material, biological, animal-source Australia - englanti - Department of Health (Therapeutic Goods Administration)

mastergraft putty - bone implant material, biological, animal-source

medtronic australasia pty ltd - 46425 - bone matrix implant, animal-derived, bioabsorbable - mastergraft? putty is supplied as a sterile, dry, solid, construct that is hydrated for single patient use and is a mouldable form of bone void filler. mastergraft? products are biocompatible, osteoconductive, porous implants that allows for bony in growth across the graft site while resorbing at a rate consistent with bone healing. mastergraft? putty is intended to help fill voids or gaps in bone, which may be surgically created osseous defects, or osseous defects caused by traumatic injury to the bone. mastergraft? putty provides a bone void filler that is resorbed and is replaced with bone during the natural healing process. the putty when combined with either autogenous bone marrow, and/or sterile water, and/or autograft is indicated as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. additionally, mastergraft putty can be used with autograft as a bone extender. specific indications for use include oral/maxillofacial augmentation or reconstruction.

BOSENTAN CIPLA bosentan 125 mg (as monohydrate) tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 125 mg (as monohydrate) tablet blister pack

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 125 mg (as monohydrate) tablet bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 125 mg (as monohydrate) tablet bottle

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 62.5 mg (as monohydrate) tablet blister pack Australia - englanti - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 62.5 mg (as monohydrate) tablet blister pack

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 62.5 mg  (as monohydrate) tablet bottle Australia - englanti - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 62.5 mg (as monohydrate) tablet bottle

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

GERM FREE INSTANT HAND SANITIZER- hand sanitizer gel Yhdysvallat - englanti - NLM (National Library of Medicine)

germ free instant hand sanitizer- hand sanitizer gel

guangzhou mengfeishi pharmaceutical technology co., ltd. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - clean and bacteriostatic, inhibit staphylococcus aureus, escherichia coli, candida albicans. prevent bacterial growth

GERM FREE DISINFECTANT GEL- hand sanitizer gel Yhdysvallat - englanti - NLM (National Library of Medicine)

germ free disinfectant gel- hand sanitizer gel

guangzhou mengfeishi pharmaceutical technology co., ltd. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antibacterial sterilization hand sanitizer to help reduce bacteria that potentially can cause disease. for use when soap and water are not available.